Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola [Yahoo! Finance]
Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola
Cibus, Inc. (NASDAQ: CBUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Cibus Inc (CBUS) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... [Yahoo! Finance]
Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2024